Interferon-γ induced by administration of recombinant interleukin-2 to patients with cancer: Kinetics, dose dependence, and correlation with physiological and therapeutic response

Michael W. Konrad, Susanne K. DeWitt, Edward C. Bradley, Gary Goodman, Eric C. Groves, Evan M. Hersh, Robert L. Krigel

Research output: Contribution to journalArticle

7 Scopus citations


The administration of recombinant interleukin-2 as an i.v. bolus at dose levels of from 1 to 30 MIU/m2to patients with cancer induces easily measurable serum interferon-γ levels of 1 to 500 U/ml. After a lag of 1 h, interferon-γrises to a maximum at 4 h and then slowly decreases. The peak values are poorly correlated with the dose of interleukin-2, and thus must be also be dependent on other factors. Successive administration of interleukin-2 typically increases the peak level of interferon-γfourfold, but does not diminish the lag period. Peak levels of interferon-γ are also increased by concurrent administration of interferon-β with interleukin-2. Continuous i.v. infusion of 1.5 to 20 MIU/m2of interleukin-2/day results in interferon-γlevels of 1 to 7 U/ml. Hypotension, which is characteristically associated with interleukin-2 administration, is correlated with interferon-γlevels in only some patients. There was no apparent correlation between tumor regression and serum interferon-γlevels.

Original languageEnglish (US)
Pages (from-to)55-63
Number of pages9
JournalJournal of Immunotherapy
Issue number1
StatePublished - Jul 1992



  • Interferon-β
  • Interferon-γ Cancer
  • Interleukin-2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this